. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol 288: H1851-H1858, 2005. First published December 9, 2004; doi:10.1152/ajpheart.00362.2004.-Adenosine and adenosine A2A receptor agonists have been shown to limit myocardial infarct size when given at vasodilatory doses during reperfusion. This beneficial effect is thought to be due, in part, to stimulation of adenosine A2A receptors on inflammatory cells. The specific aims of this study were to determine whether the antiinflammatory and cardioprotective properties of a novel adenosine A2A receptor agonist, ATL-146e (ATL), alone or in combination with the phosphodiesterase IV inhibitor rolipram would occur using very low, nonvasodilating doses. In a canine model of reperfused myocardial infarction, low-dose ATL given alone reduced infarct size by 45% (P Ͻ 0.05 vs. control). When ATL was combined with a very low dose of rolipram (0.001 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), a marked reduction in P-selectin expression and neutrophil infiltration (51% lower; P Ͻ 0.001 vs. control) was seen and the infarct size reduction (58% lower; P Ͻ 0.01 vs. control) was greater than observed with ATL (45% lower; P Ͻ 0.05) or rolipram (33% lower; P Ͻ 0.05) alone. In conclusion, a low, nonvasodilating dose of ATL, a highly selective adenosine A2A receptor agonist, reduced infarct size after reperfusion. Furthermore, combining ATL and the phosphodiesterase IV inhibitor rolipram reduced infarct size even more than either agent alone. Such combination therapy may be beneficial clinically by potentiating cardioprotection after coronary reperfusion at doses far below those producing vasodilatation or side effects. myocardial infarction IN EXPERIMENTAL AND CLINICAL STUDIES, adenosine has been shown to limit infarct size and/or improve left ventricular function when administered at the time of coronary reperfusion (20, 21, 28) . The mechanism for this protection is not well understood. Postischemic inflammation is known to be a major component of reperfusion injury involving the release of oxygen free radicals, cytokines, and proteases from infiltrating neutrophils in the reperfused zone (7).
. The potent anti-inflammatory response to these agonists is mediated through stimulation of the G s protein-coupled A 2A receptor subtype on neutrophils, mast cells, T cells, and platelets, resulting in elevation of intracellular cAMP and activation of protein kinase A, leading to the inhibition of multiple steps in the inflammatory cascade (11, 24, 25, 42, 45) . Phosphodiesterase (PDE) type IV inhibitors, such as rolipram, also inhibit inflammation by increasing intracellular cAMP levels (32) and have been shown to act synergistically with adenosine A 2A receptor agonists in reducing neutrophil activation (42) and postischemic tissue injury in the kidney (26) .
In the present study, we hypothesized that an adenosine A 2A receptor agonist would afford cardioprotection in reperfused myocardium without the necessity of increasing flow. A secondary hypothesis was that, based on the synergy observed with A 2A adenosine receptor agonists and rolipram in reducing postischemic injury in other tissues and models at our institution (26, 42) , the reduction in myocardial infarct size with the combination of ATL-146e ϩ rolipram would be greater than with either drug alone and would be associated with a greater decrease in neutrophil accumulation in the reperfused zone.
The specific aims of this study were to determine whether stimulation of the adenosine A 2A receptor subtype offers cardioprotection from reperfusion injury and whether the antiinflammatory and infarct size-limiting properties of adenosine A 2A receptor agonists are further enhanced when combined with a PDE type IV inhibitor.
MATERIALS AND METHODS
All animal experiments were performed with the approval of the University of Virginia Animal Care and Use Committee and were in compliance with the position of the American Heart Association on the use of research animals.
In Vitro Neutrophil Oxidative Burst Assay
Twenty-five milliliters of venous dog blood were heparinized (10 U/ml), centrifuged (200 g for 8 min), and processed as previously described in detail (42) . The effect of ATL-146e (1-1,000 nM) and ATL-146e ϩ rolipram (300 nM, Cedar Knolls, NJ) on neutrophil oxidative burst was assessed as previously described (35) . The in vitro samples containing mixed leukocytes were gated for neutrophils by forward and side scatter, and the fluorescence of 10,000 neutrophils was measured in the FL1 channel of a FACScan (Becton-Dickinson) flow cytometer. The results are reported as relative mean fluorescence intensity. Each point is the mean Ϯ SE of nine samples from three different dogs.
In Vivo Canine Experiments
Surgical preparation and experimental protocol. Thirty-two fasted, adult mongrel dogs (mean 23.3 Ϯ 0.6 kg, range 17.3-29.5 kg) were anesthetized with pentobarbital sodium (30 mg/kg iv), tracheally intubated, and mechanically ventilated with room air (Harvard Apparatus). Open-chest surgery and instrumentation were performed as previously described (8, 35) .
After a 30-min baseline stabilization period, the left anterior descending coronary artery (LAD) and all visible collaterals were totally occluded for 90 min and reperfused for 120 min. Myocardial surface temperature was monitored and adjusted to match the animal's core temperature. Regional myocardial blood flows were assessed using radiolabeled microspheres during baseline (10 min before occlusion) and at the end of the occlusion and reperfusion periods. Intravenous infusions of ATL-146e (0.01 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; n ϭ 5) and rolipram (0.001 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; n ϭ 5) were tested separately and combined. The separate drug infusions were begun at baseline, 5 min before LAD occlusion, whereas the combination ATL-146e (0.01 or 0.001
) treatment was begun either at baseline (5 min before LAD occlusion; n ϭ 10) or 30 min before coronary reperfusion (n ϭ 5) and continued throughout the protocol. The maximum dose of ATL-146e that was administered (0.01 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) is below the threshold for producing a vasodilatory response in dogs (8) . A control group of seven dogs had no treatment. Myocardial inflammation was assessed with the neutrophil tracer 99m Tc-RP517 35 and by postmortem immunohistochemical techniques. Before euthanasia, the LAD was briefly reoccluded and 40 ml of monastral blue dye were rapidly injected into the left atrial catheter to delineate the anatomic risk area.
Postmortem Analysis
Immunohistochemistry. Myocardial biopsies were taken from the normal and infarct areas immediately after excision of the hearts, fixed overnight in 4% paraformaldehyde, and paraffin embedded. Sections were analyzed for P-selectin expression using a rabbit polyclonal anti-P-selectin antibody (10), as previously described (12) , and neutrophil staining was performed using naphthol AS-D chloroacetate esterase (18) . Sections were observed microscopically, and the images were digitized through an Olympus (BH-2) microprojection system with a Dage-MTI DC-330 color camera (Dage-MTI).
Ex vivo image acquisition and analysis. After excision, the hearts were sliced evenly into four rings from apex to base and placed directly on the collimator of a gamma camera (Siemens Orbiter) for quantitative ex vivo imaging of 99m Tc-RP517 activity, as previously described (35) .
Determination of regional myocardial blood flow and 99m Tc-RP517 myocardial activity. The technique used in our laboratory to quantify regional myocardial blood flow by the radioactive microsphere technique has been described previously (8) . Seventy-two epicardial, midwall, and endocardial segments and arterial blood samples were counted in a gamma-well counter (MINAXI 5550, Packard Instruments) using standard methods in our laboratory (8, 35) . Transmural flow values were calculated as the weighted average of the corresponding epicardial, midwall, and endocardial samples.
99m Tc-RP517 activity in each myocardial segment was expressed as a percentage of the average 99m Tc-RP517 activity in the five normal, left circumflex zone segments from the same animal exhibiting the highest flow during occlusion.
99m Tc-RP517 myocardial uptake was averaged in myocardial segments that had 0 -40% of normal flow during occlusion.
Determination of risk area and infarct size. The heart slices were incubated for 10 min at 37°C in a 2% solution of triphenyl tetrazolium chloride to delineate infarct area. Pictures of myocardial slices were obtained with a digital camera (Olympus D-600L), and the risk and infarcted areas were determined with specialized computer software (SigmaScan Pro Image Analysis version 5.0.0, SPSS).
Statistical Analysis
Results are presented as means ϮSE. Computations were performed with SYSTAT software (SPSS). Treatment and time effects for regional myocardial blood flow were analyzed using two-way repeated-measures ANOVA. Comparisons between treatment groups for all other parameters were assessed using one-way ANOVA. When appropriate, post hoc testing was performed using Bonferroni's tests. P values of Ͻ0.05 were considered significant.
RESULTS

In Vitro Neutrophil Oxidative Burst Assay
The in vitro results using canine neutrophils are depicted in Fig. 1 . ATL-146e decreased neutrophil oxidative burst in a dose-dependent manner (P Ͻ 0.001 by repeated-measures ANOVA), with a 23% inhibition at the 1 M dose. Combination of ATL-146e with rolipram had a synergistic, inhibitory effect greater than with ATL-146e or alone at all common doses tested (P Ͻ 0.01 vs. ATL-146e). Oxidative activity of stimulated neutrophils in the presence of 10 nM ATL-146e ϩ 300 nM rolipram was similar to the basal activity of unstimulated cells.
In Vivo Canine Experiments
Hemodynamic parameters. The mean hemodynamic parameters of aortic pressure, heart rate, and first derivative of left ventricular pressure (dP/dt) are presented in Table 1 . Despite some minor changes of these parameters within each group over time, no statistical differences between groups in any of the hemodynamic parameters were observed.
Regional myocardial blood flow. Endocardial, midwall, epicardial, and transmural regional blood flows are presented in Table 2 . After LAD occlusion, endocardial and transmural flows fell significantly. Endocardial flow was Ͻ0.15 ml⅐min Ϫ1 ⅐g Ϫ1 in all groups and was restored to baseline within 120 min after reperfusion. No statistical difference in the severity of endocardial and transmural flow reduction during occlusion between the control and treated groups was seen. Furthermore, regression analysis of the data from all 32 dogs included in this study showed no correlation (r 2 ϭ 0.08) between infarct size and residual blood flow during the occlusion period. The slope of the regression line was not significantly different from zero.
Assessment of Myocardial Inflammation
Immunohistochemistry. Immunohistochemical analysis of Pselectin and Leder staining of neutrophils from a representative control and ATL-146e ϩ rolipram-treated dog are presented in Fig. 2 . P-selectin expression and neutrophil infiltration were visibly reduced in the ATL-146e ϩ rolipram-treated dog. Observation at higher magnification also revealed better myocyte structural integrity with less edema and cellular disruption in the treated group of dogs.
99m Tc-RP517. Myocardial uptake of the neutrophil tracer 99m Tc-RP517 in reperfused myocardium as measured by gamma well counting and ex vivo imaging is presented in Fig.  3 . As shown in Fig. 3A , ATL-146e or rolipram alone reduced neutrophil infiltration by 31 and 37%, respectively, whereas the combination of ATL-146e ϩ rolipram reduced neutrophil infiltration by 51 and 22% when the treatment was begun at baseline or reperfusion, respectively (P Ͻ 0.01 vs. control). Representative ex vivo images of 99m Tc-RP517 uptake are presented in Fig. 3B . As observed with gamma-well counting, mean 99m Tc-RP517 reperfused to normal zone ratios were reduced by 48 and 20% with ATL-146e ϩ rolipram when the treatment was begun at baseline or reperfusion, respectively (P Ͻ 0.05 and P ϭ not significant, respectively, vs. control).
Risk area and reduction in infarct size. Myocardial risk area was similar between the experimental groups (Fig. 4) . Infarct area in control animals represented 56.8 Ϯ 6.4% of the risk area.
ATL-146e alone. Treatment with ATL-146e alone, beginning at baseline, resulted in a 45% decrease in myocardial infarct size to 31.3 Ϯ 8.7% compared with the control group (P Ͻ 0.05).
Rolipram alone. Treatment with rolipram alone beginning at baseline resulted in a 33% reduction in myocardial infarct size to 38.0 Ϯ 6.5% compared with the control group (P Ͻ 0.05).
ATL-146e Ϯ rolipram combination. Treatment with ATL146e ϩ rolipram beginning either at baseline or reperfusion resulted in a marked 58 and 50% decrease in myocardial infarct size, respectively (P Ͻ 0.01 vs. control). There was no statistical difference in infarct size reduction when ATL-146e ϩ rolipram was given at baseline vs. given just before reperfusion. The combination treatment resulted in a decrease in myocardial infarct size that was greater than seen with ATL146e or rolipram alone.
DISCUSSION
In canine models of myocardial infarction, low-dose, intravenous administration of the highly selective adenosine A 2A receptor agonist ATL-146e significantly reduced infarct size, both as a pretreatment and when administered just before reperfusion, without causing vasodilatation. Rolipram is a PDE type IV inhibitor that, given alone, resulted in a 33% reduction in infarct size. When both ATL-146e and rolipram were given in combination, infarct size was reduced by 58%. This beneficial effect corresponded with a marked reduction in myocardial inflammation.
Comparison With Previous Experimental Studies
There have been conflicting results using adenosine administered at reperfusion for cardioprotection. In a canine model of myocardial infarction, Pitarys et al. (30) found that adenosine infusion in the early reperfusion period markedly reduced infarct size from 35 to 17% of the risk area, and the protection was sustained over 72 h. In contrast, Vander Heide and colleagues (44) found no reduction in infarct size with intravenous adenosine in a canine model of 90 min of coronary ) was begun either at Base or reperfusion (Rep). *P Ͻ0.05 vs. Base within a group. There were no significant differences in hemodynamics between the groups at any time point. occlusion and reperfusion. Likewise, Goto et al. (9) found that intravenous adenosine infusion during early reperfusion failed to limit myocardial infarct size in rabbits.
The variability in these studies, in part, may be that, in addition to the potent anti-inflammatory effect of A 2A adenosine receptor stimulation, adenosine produces proinflammatory responses mediated by receptors that vary among species; A 3 and A 2B receptors mediate degranulation of rodent and human or canine mast cells, respectively (2, 6, 33) . In contrast to the variable results obtained using adenosine, a number of experimental studies have all demonstrated the cardioprotective effects of an adenosine A 2A receptor agonist (CGS-21680) given at the time of reperfusion (11, 16, 23, 36) . Infarct size reduction ranged from 40 to 60% when given via the intracoronary route in canine and swine models (11, 16, 36) and 42% when an intermediate dose was administered intravenously in rabbits (23). Values are means Ϯ SE expressed as ml ⅐ min Ϫ1 ⅐ g Ϫ1 . The combination ATL-146e (0.01 or 0.001 g⅐kg Ϫ1 ⅐min Ϫ1 ) ϩ rolipram (0.001 g⅐kg Ϫ1 ⅐min Ϫ1 ) was begun either at Base or Rep. *P Ͻ0.05 vs. Base within a group. There were no significant differences in endocardial, midwall, epicardial, or transmural flow between the different treatment groups in either the normal or ischemic zones at any time point.
Marked infarct size reduction has also been reported in rabbits, dogs, and pigs with AMP579, a mixed adenosine A 1 /A 2 adenosine receptor agonist, when given at the time of coronary reperfusion (3, 13, 39, 46) . The mechanism for the AMP 579-mediated protection when given at reperfusion has been shown to involve the adenosine A 2A receptor (13) . In most of these animal studies, the AMP579 dose given produced hemodynamic changes, including vasodilatation; however, in one study, significant infarct size reduction (50%) was found in a pig model at a low, hemodynamically silent dose (3 g/kg bolus ϩ 0.3 g⅐ kg Ϫ1 ⅐min Ϫ1 infusion) (39) . Unfortunately, the results of a recent clinical trial (ADMIRE) showed no reduction of infarct size with AMP579 treatment (14) .
Synergism with ATL-146e and a PDE Type IV Inhibitor
A major finding of the present study was that the reduction in myocardial infarct size and postischemic inflammation was enhanced when the adenosine A 2A receptor agonist ATL-146e was combined with the PDE type IV inhibitor rolipram. ATL146e alone and rolipram alone (see Fig. 4 ) resulted in a reduction in ischemic reperfusion injury, but the effect of the combination treatment was greater than observed for either agent alone. The synergism between an adenosine A 2A receptor agonist and rolipram in inhibiting oxidative burst in activated neutrophils was demonstrated in this study using canine neutrophils and has previously been observed when the same in vitro assay was performed on neutrophils obtained from human donors (40) . Synergism between rolipram and adenosine or adenosine A 2A receptor agonists has also been shown in vivo in animal models of meningitis (41) and renal ischemia/ reperfusion (26) .
In the present study, we also found that a very low dose (1 ng⅐kg Ϫ1 ⅐min Ϫ1 ) of the PDE type IV inhibitor rolipram alone produced a significant reduction in both inflammation and infarct size (reduced 33%). Rolipram was most likely acting in conjunction with the endogenous adenosine produced during the ischemic period to maintain elevated cAMP levels and to reduce inflammation and infarct size. Our results with rolipram alone differ in part from those reported by other laboratories. McVey et al. (22) administered rolipram at the time of reperfusion to see whether it would reduce infarct size in a reperfused rat heart model. In their study, rolipram reduced the inflammatory response as measured by the production of TNF-␣ but did not reduce infarct size. It is possible that any protective effect of rolipram in their study was offset by the marked hypotension that was observed at the dose of rolipram given. Hypotension may have attenuated repefusion flow and exacerbated or prolonged the ischemic period. In another study, Simpson et al. (38) gave rolipram before reperfusion in a canine model. They also found a tendency for a reduction in the level of the neutrophil marker tissue myeloperoxidase (P ϭ 0.0548) with attenuation of the "no-reflow" phenomenon but no reduction in infarct size. One difference between their study and the present study is that we tied off all of the visible collateral vessels during the occlusion period. This would be expected to produce more severe ischemia and may have Fig. 2 . Immunohistochemical and Leder staining of P-selectin (top) and neutrophils (bottom), respectively, in a representative dog from the control (left) and treated (prereperfusion; right) groups. Inset: vessel denoted by arrow at a higher magnification (ϫ1,000). As can be seen, both P-selection expression and neutrophil infiltration were visibly reduced in the treated dog, confirming the inhibition of inflammation by ATL146e ϩ rolipram treatment.
resulted in a greater production of endogenous adenosine, as well as slowing its washout from the interstitium, during the ischemic period. Zhao et al. (47) reported that endogenous adenosine released from the myocardium during ischemiareperfusion reduces infarct size by an adenosine receptormediated mechanism and that the protection is most pronounced during the early phase of reperfusion. Thus, in our study, a higher level of endogenous adenosine may have been available to act synergistically with rolipram at the time of reperfusion to protect the myocardium.
Reduction of Myocardial Inflammation After Reperfusion
In the previous experimental studies using CGS21680 (11, 16, 23, 36) , the administered dose of the A 2A agonist was sufficient to produce vasodilatation, especially when adminis- Fig. 3 . A: assessment of canine myocardial inflammation with the neutrophil tracer 99m Tc-RP517 as measured by gamma well counting of tissue segments.
99m Tc-RP517 activity in endocardial and midwall segments with 0 -40% of normal flow during coronary occlusion was expressed as a percentage of tracer activity in the normal, nonischemic zone. The ATL-146e ϩ rolipram combination reduced neutrophil infiltration by 51 and 22% when administered at baseline or reperfusion, respectively, and the anti-inflammatory effect was greater than with either agent alone. Base, baseline; Rep, reperfusion. B: representative ex vivo images of 99m Tc-RP517 canine myocardial activity after ischemia and reperfusion in a control dog (left) and an animal treated with ATL-146e ϩ rolipram (right). Note that neutrophil infiltration in the previously ischemic area was markedly reduced in the presence of ATL146e ϩ rolipram. The combination treatment of ATL-146e ϩ rolipram provided greater protection than with either agent alone. Note that the reduction in infarct size when ATL-146e ϩ rolipram was administered at reperfusion (decrease of 58%) was similar to that when given during baseline (decrease of 50%). LV, left ventricle; RA, risk area. tered by the intracoronary route. Although significant cardioprotection was observed in all of these studies, it is impossible to determine whether the observed infarct size reduction was due to a decrease in inflammation, an improvement in tissue perfusion, or a combination of both. In the present study, we gave very low doses of ATL-146e and rolipram that produced no increase in regional myocardial blood flow, yet resulted in a marked reduction in inflammation, as evidenced by inhibition of P-selectin expression and neutrophil infiltration and a 51-58% reduction in myocardial infarct size. Although we chose P-selectin and neutrophils as general markers of the inflammatory response, we cannot rule out an inhibitory effect of the treatment on other inflammatory cell types [e.g., T-lympocytes (4, 15, 17)], tissue cytokines or chemokines, or platelet activation (17, 31) .
Clinical Implications
Optimal coronary reperfusion after acute myocardial infarction must result not only in early and sustained patency of the epicardial coronary vessel but maintenance of microvascular flow and tissue perfusion. Reperfusion injury and microvascular no-reflow may attenuate the benefit of reperfusion therapy aimed at reducing infarct size (34) .
Myocardial inflammation may be one mechanism contributing to microvascular injury after reperfusion. Intravascular plugging by activated leukocytes may inhibit nutrient blood flow to the myocardium (37) . Leukocytes also promote release of oxygen-free radicals and cytokines that induce further injury to the capillary endothelium. Several pharmacological approaches to inhibiting this myocardial inflammatory response consequent to ischemia/reperfusion have been examined in the clinical setting. The AMISTAD trial reported a 33% relative reduction in infarct size with adenosine (20) .
Although experimental studies appeared promising (1, 19, 43) , a clinical trial using an antibody (Hu23F2G) to block the CD11/CD18 integrin receptor proved negative (5) . It should be pointed out that the dose of Hu23F26 used had only saturated 80% of the granulocyte receptors.
In the present experimental study, administration of an adenosine A 2A receptor agonist and a PDE type IV inhibitor alone significantly reduced both infarct zone inflammation after reperfusion and infarct size in a canine model of occlusion and reperfusion. Whether such an impressive outcome would be seen in patients treated with these compounds is yet unknown. Certainly, the highly selective adenosine A 2A receptor agonist may be more effective than adenosine since it is specific for the A 2A receptor eliminating the A 2B effects of hypotension and the A 1 proinflammatory and adverse electrophysiological effects. A clinical trial testing this hypothesis appears warranted.
Study Limitations
One limitation of our study is that we did not test higher doses of ATL-146e and rolipram than those reported. As mentioned above, we selected nonvasodilatory doses to avoid the confounding effect of increased flow on the interpretation of the mechanism for cardioprotection. Higher vasodilating doses of ATL-146e and rolipram might confer greater protection but possibly at the expense of increased side effects.
A second limitation is that, in these acute studies, we were unable to address the question of long-term outcome after short-term treatment. Specifically, does the benefit of infarct size reduction translate into improved cardiac function and enhanced survival in the long term? Further studies in chronic models of myocardial infarction and in humans are needed to address this very important question.
